Contract manufacturer Kemwell will produce drugs for Mercury Pharma at a plant that it bought in 2006 from Pfizer ($PFE). While it still has capacity at the facility, the company said it has nailed down three other contracts, proof that drugmaking in Sweden is on the rise, Outsourcing-Pharma.com reports. "This contract with Mercury is very valuable for us and a most interesting contract in manufacturing but also a proof that Sweden is a competitive country in pharmaceutical production," business development manager Leo Fallgren told the publication. The India-based company added to the 16,000-square-meter former Pfizer plant in 2010, boosting its operations space to 31,000 square meters. Mercury Pharma, a U.K.-based specialty drugmaker, was recently acquired by Cinven for £465 million ($756 million). Story | More